Deutsche Bank Ag\ Arbutus Biopharma Corp Transaction History

Deutsche Bank Ag\

$248 Billion
Q4 2024

A detailed history of Deutsche Bank Ag\ transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Deutsche Bank Ag\ holds 171,766 shares of ABUS stock, worth $575,416. This represents 0.0% of its overall portfolio holdings.

Number of Shares

171,766

Previous 96,554 77.9%

Holding current value

$575,416

Previous $371,000 51.21%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$3.18 - $4.2 $239,174 - $315,890	75,212 Added 77.9%	171,766 $561,000
Q3 2024 Nov 13, 2024	BUY	$3.12 - $4.56 $74,128 - $108,341	23,759 Added 32.64%	96,554 $371,000
Q2 2024 Aug 14, 2024	SELL	$2.52 - $3.63 $158 - $228	-63 Reduced 0.09%	72,795 $224,000
Q1 2024 May 15, 2024	BUY	$2.26 - $2.92 $14,269 - $18,436	6,314 Added 9.49%	72,858 $187,000
Q4 2023 Feb 14, 2024	SELL	$1.69 - $2.54 $4,738 - $7,122	-2,804 Reduced 4.04%	66,544 $166,000
Q3 2023 Nov 09, 2023	BUY	$1.9 - $2.27 $26,292 - $31,412	13,838 Added 24.93%	69,348 $140,000
Q2 2023 Aug 14, 2023	SELL	$2.24 - $3.06 $36,841 - $50,327	-16,447 Reduced 22.86%	55,510 $127,000
Q1 2023 May 15, 2023	BUY	$2.23 - $3.1 $48,382 - $67,257	21,696 Added 43.17%	71,957 $218,000
Q4 2022 Feb 13, 2023	BUY	$1.91 - $2.85 $1,375 - $2,052	720 Added 1.45%	50,261 $117,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $13,567 - $20,784	-7,217 Reduced 12.72%	49,541 $94,000
Q2 2022 Aug 11, 2022	BUY	$1.98 - $3.17 $26,143 - $41,856	13,204 Added 30.32%	56,758 $154,000
Q1 2022 May 13, 2022	SELL	$2.42 - $3.98 $12,695 - $20,879	-5,246 Reduced 10.75%	43,554 $130,000
Q4 2021 Feb 11, 2022	BUY	$3.11 - $4.61 $8,036 - $11,912	2,584 Added 5.59%	48,800 $190,000
Q3 2021 Nov 04, 2021	SELL	$2.65 - $4.62 $873,273 - $1.52 Million	-329,537 Reduced 87.7%	46,216 $198,000
Q2 2021 Aug 11, 2021	BUY	$2.5 - $3.51 $807,965 - $1.13 Million	323,186 Added 614.81%	375,753 $1.14 Million
Q1 2021 May 13, 2021	BUY	$3.14 - $4.84 $165,060 - $254,424	52,567 New	52,567 $175,000
Q4 2020 Feb 16, 2021	SELL	$2.76 - $4.97 $352,686 - $635,091	-127,785 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$1.75 - $6.2 $223,623 - $792,267	127,785 New	127,785 $400,000
Q1 2020 May 14, 2020	SELL	$1.01 - $3.42 $1,759 - $5,957	-1,742 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$0.87 - $2.89 $11,370 - $37,772	-13,070 Reduced 88.24%	1,742 $4,000
Q3 2019 Nov 14, 2019	SELL	$1.34 - $2.4 $77,981 - $139,668	-58,195 Reduced 79.71%	14,812 $22,000
Q2 2019 Aug 14, 2019	SELL	$1.46 - $4.44 $84,894 - $258,172	-58,147 Reduced 44.33%	73,007 $150,000
Q1 2019 May 15, 2019	BUY	$3.41 - $4.57 $68 - $91	20 Added 0.02%	131,154 $468,000
Q4 2018 Feb 14, 2019	SELL	$3.5 - $9.66 $110,148 - $304,009	-31,471 Reduced 19.35%	131,134 $501,000
Q3 2018 Dec 21, 2021	BUY	$7.85 - $12.35 $135,938 - $213,864	17,317 Added 11.92%	162,605 $1.54 Million
Q3 2018 Nov 14, 2018	BUY	$7.85 - $12.35 $317,249 - $499,112	40,414 Added 38.54%	145,288 $1.37 Million
Q2 2018 Apr 21, 2020	BUY	$5.0 - $7.35 $90,025 - $132,336	18,005 Added 20.73%	104,874 $765,000
Q2 2018 Aug 14, 2018	BUY	$5.0 - $7.35 $109,780 - $161,376	21,956 Added 33.82%	86,869 $633,000
Q1 2018 Oct 18, 2019	BUY	$4.4 - $6.05 $29,374 - $40,389	6,676 Added 11.46%	64,913 $324,000
Q1 2018 May 15, 2018	SELL	$4.4 - $6.05 $462,941 - $636,544	-105,214 Reduced 64.37%	58,237 $291,000
Q4 2017 Feb 14, 2018	BUY	$4.45 - $7.7 $144,406 - $249,872	32,451 Added 24.77%	163,451 $825,000
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $445,400 - $917,000	131,000	131,000 $811,000

Others Institutions Holding ABUS

# of Institutions

164

Shares Held

101M

Call Options Held

649K

Put Options Held

666K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $502M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account